Search results
Does Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect?
Zacks via Yahoo Finance· 2 years agoThe mean of analysts' price targets for Atara Biotherapeutics (ATRA) points to a 204.1% upside in...
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
Zacks via Yahoo Finance· 8 months agoAtara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product...
Atara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnership
GuruFocus.com via Yahoo Finance· 6 months agoAtara Biotherapeutics Inc (NASDAQ:ATRA) announced its Q3 2023 financial results and an expanded...
Virginia Beach wants to change its noise ordinance to quiet buskers on the Boardwalk
Virginian Pilot via Yahoo News· 2 years agoJahsun Ma’atra is a traveling musician who likes to perform in public areas at beaches along the...
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoAtara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%,...
After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners...
Simply Wall St. via Yahoo Finance· 3 months agoKey Insights Institutions' substantial holdings in Atara Biotherapeutics implies that they have...
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be
Simply Wall St. via Yahoo Finance· 12 months agoToday is shaping up negative for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shareholders, with the...
Atara Biotherapeutics (NASDAQ:ATRA) shareholders are up 17% this past week, but still in the red...
Simply Wall St. via Yahoo Finance· 2 years agoThis week we saw the Atara Biotherapeutics, Inc. (NASDAQ:ATRA) share price climb by 17%. But only...
Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 2 days agoAtara Biotherapeutics (NASDAQ:ATRA) First Quarter 2024 Results Key Financial Results Revenue:...
The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues Yet
Simply Wall St. via Yahoo Finance· 1 year agoAtara Biotherapeutics, Inc.'s (NASDAQ:ATRA) price-to-sales (or "P/S") ratio of 4.4x might make it...